polymers Article Effect of Crystallinity on the Properties of Polycaprolactone Nanoparticles Containing the Dual FLAP/mPEGS-1 Inhibitor BRP-187 Antje Vollrath 1,2, Christian Kretzer 3, Baerbel Beringer-Siemers 1, Blerina Shkodra 1,2 , Justyna A. Czaplewska 1,2, Damiano Bandelli 1,2, Steffi Stumpf 1,2, Stephanie Hoeppener 1,2 , Christine Weber 1,2 , Oliver Werz 2,3 and Ulrich S. Schubert 1,2,* 1 Laboratory of Organic Chemistry and Macromolecular Chemistry (IOMC), Friedrich Schiller University, Humboldtstraße 10, 07743 Jena, Germany;
[email protected] (A.V.);
[email protected] (B.B.-S.);
[email protected] (B.S.);
[email protected] (J.A.C.);
[email protected] (D.B.); steffi
[email protected] (S.S.);
[email protected] (S.H.);
[email protected] (C.W.) 2 Jena Center for Soft Matter (JCSM), Friedrich Schiller University, Philosophenweg 7, 07743 Jena, Germany;
[email protected] 3 Department of Pharmaceutical/Medicinal Chemistry, Institute of Pharmacy, Friedrich Schiller University, Philosophenweg 14, 07743 Jena, Germany;
[email protected] * Correspondence:
[email protected] Citation: Vollrath, A.; Kretzer, C.; Abstract: Seven polycaprolactones (PCL) with constant hydrophobicity but a varying degree of crys- Beringer-Siemers, B.; Shkodra, B.; tallinity prepared from the constitutional isomers "-caprolactone ("CL) and δ-caprolactone (δCL) were Czaplewska, J.A.; Bandelli, D.; utilized to formulate nanoparticles (NPs). The aim was to investigate the effect of the crystallinity of Stumpf, S.; Hoeppener, S.; Weber, C.; the bulk polymers on the enzymatic degradation of the particles.